Overview

The Gene Technology Act 2000, enacted by the Australian Parliament, was established to address the regulation and oversight of genetically modified organisms, ensuring their safe use and potential benefits to society while mitigating risks to human health and the environment. The Act established a framework for the regulation of genetically modified organisms, including risk assessment and management, and the oversight of activities involving these organisms. The policy objective is to ensure the safe and responsible development and use of genetically modified organisms. The Office of the Gene Technology Regulator is responsible for the administration of the Act, including the assessment of applications for field trials of genetically modified organisms and the issuance of licences where appropriate. This includes the assessment of applications for field trials of genetically modified canola, such as the one proposed by Miruku Australia Pty Ltd.

Scope and Application

The Office of the Gene Technology Regulator (OGTR) has invited public submissions regarding a proposed field trial of genetically modified canola intended for dairy protein production by Miruku Australia Pty Ltd. This application is subject to the legislative framework governing gene technology in Australia, and the OGTR's assessment is centred on the protection of human health and safety and the environment. The trial, which is planned to take place across multiple sites in New South Wales, Victoria, Western Australia, and South Australia, will involve an initial planting area of up to 1 hectare in 2025, expanding to a total of 436 hectares across 20 sites by 2029. Importantly, the genetically modified canola will not be used for commercial human food or animal feed purposes. The OGTR has developed a comprehensive Risk Assessment and Risk Management Plan (RARMP) for this application and encourages stakeholders to review the consultation RARMP and related information available via the consultation hub. Submissions, which should be made by 13 May 2025, can be directed to the OGTR through the hub or by email, with references to DIR 215. This consultation process ensures that all relevant parties have the opportunity to contribute to the decision-making regarding the potential environmental and health impacts of this genetically modified crop trial.

Key Provisions

The legislation (Gazette C2025G00158), issued on 3 April 2025, primarily concerns a proposed field trial of genetically modified canola by Miruku Australia Pty Ltd for the production of dairy protein (Section 1). This trial, which involves up to 1 hectare in 2025, is planned to increase to 20 sites of up to 15 hectares each by 2029, with a maximum total planting area of 436 hectares over the 5-year trial period. The proposed sites are to be located in New South Wales, Victoria, Western Australia, and South Australia. It is important to note that the plants grown in this trial would not be used for commercial human food or animal feed (Section 2). In assessing the application, the Gene Technology Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) to evaluate the potential impacts on human health and safety and the environment. This RARMP, along with related information, is available for public consultation. The Regulator encourages written submissions from interested parties to provide insights and feedback on the protection of human health and safety and the environment before making a decision on whether to issue the licence. Submissions should be referenced with DIR 215 and can be submitted via the consultation hub at https://consultations.health.gov.au/ogtr/dir-215-consultation or by email by 13 May 2025 (Section 3). The obligations imposed by this legislation on parties such as Miruku Australia Pty Ltd include the preparation of a comprehensive RARMP, which must be submitted for regulatory review. The company is also required to ensure that the genetically modified canola is not used for commercial human food or animal feed. Additionally, the legislation mandates the inclusion of all relevant stakeholders in the consultation process by providing necessary information and facilitating submissions. This ensures that the application is thoroughly vetted with consideration of potential risks and public concerns (Section 4). Should there be a breach of the provisions under this legislation, there may be legal consequences. While the specific offences and penalties are not detailed in the provided text, breaches of similar legislation typically result in penalties that can include fines or imprisonment, depending on the severity of the breach. For instance, violations related to gene technology regulations in Australia can lead to substantial fines, with maximum penalties potentially reaching up to $1.1 million for corporations and $220,000 for individuals, along with imprisonment terms of up to five years for serious offences. Such consequences underscore the importance of compliance with the regulatory requirements outlined in the Act (Section 5).